Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016

Go back to Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016

Exact Sciences (EXAS) Tops Q1 EPS by 3c

May 3, 2016 7:32 AM EDT

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.49), $0.03 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $14.83 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

... More